Efficacy, Mechanisms, and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients
Clinical Journal of the American Society of Nephrology · 2026-04 · 21 (4) · 664-679
DOI: 10.2215/cjn.0000000951 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 12.12.2025. Verfasst von Vikas S Sridhar und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Glucosides, Benzhydryl Compounds, Kidney Transplantation. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Heart and Stroke Foundation of Canada, University Health Network Foundation, Ajmera Transplant Center.
Abstract (Originalsprache)
Key Points The effIcacy, mechaNisms and saFety of SGLT2 INhibitors in kIdney Transplant recIpients trial assessed the physiologic effects of sodium-glucose cotransporter-2 inhibitors in kidney transplant recipients. In kidney transplant recipients, sodium-glucose cotransporter-2 inhibitors lowered mean arterial pressure after 1 week, reduced GFR, increased glucosuria, and were safe. Dapagliflozin was well tolerated in kidney transplant recipients, showing similar cardio-kidney effects seen in other groups; outcome trials in kidney transplant recipients are now needed.
Background
Cardiovascular and kidney protective mechanisms with 12 weeks of sodium-glucose cotransporter-2 inhibitor treatment (dapagliflozin 10 mg daily) were assessed in kidney transplant recipients (KTR) with and without type 2 diabetes.
Methods
This randomized double-blind, parallel-group, placebo-controlled study enrolled 52 KTR and comprised three sequential physiologic assessments under clamped euglycemia (4–6 mmol/L): baseline, at 1, and 12 weeks of treatment. The primary objective was to evaluate BP lowering with dapagliflozin. Secondary outcomes were iohexol-measured GFR, natriuresis, body composition, noninvasive cardiac output monitoring, arterial stiffness, heart rate variability, neurohormones, and safety.
Results
Fifty-one KTR completed the study—mean age 53±13 years, 62% with hypertension, 57% with type 2 diabetes, 50% on renin-angiotensin-aldosterone system inhibitors, and mean eGFR 68.2±24.4 ml/min per 1.73 m 2 . Compared with placebo, dapagliflozin did not lower systolic BP at 1 or 12 weeks, although it did reduce mean arterial pressure after 1 week (3.9 mm Hg; 95% confidence interval [CI], −7.5 to −0.2). Dapagliflozin led to significant, placebo-adjusted reductions in iohexol-measured GFR from baseline to 1 week (4.2 ml/min per 1.73 m 2 ; 95% CI, −7.14 to −1.24 ml/min per 1.73 m 2 ) and 12 weeks (−3.49 ml/min per 1.73 m 2 ; 95% CI, −6.33 to −0.64). Dapagliflozin significantly increased glucosuria without altering proximal sodium handling or evidence of sympathetic activation. Acute decreases in arterial stiffness (carotid augmentation index, −3.5%; 95% CI, −6.0 to −1.1) were observed in the dapagliflozin group after 12 weeks, although this was not significant compared with placebo. Dapagliflozin was generally safe and well tolerated. No episodes of urinary tract or genitourinary infections were observed in either treatment group throughout the trial.
Conclusions
Dapagliflozin activated expected physiologic pathways, although key differences observed in KTR might suggest mechanistic heterogeneity compared with nontransplant populations. Clinical trials evaluating sodium-glucose cotransporter-2 inhibitors in KTR are important to determine whether these mechanistic effects translate to improvements in kidney and cardiovascular outcomes. Clinical Trial registry name and registration number: ClinicalTrials.gov, NCT04965935. Podcast This article contains a podcast at https://dts.podtrac.com/redirect.mp3//www.asn-online.org/media/podcast/JASN/2026_02_09_KTS_February2026.mp3
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
- Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Division of Nephrology, Department of Medicine, University Health Network, Toronto, Ontario, Canada.
- Biostatistics Department, University Health Network, Toronto, Ontario, Canada.
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
- Division of Nephrology, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada.
ORCID-Profile: Vikas S Sridhar, Luxcia Kugathasan, Yuliya Lytvyn, Hongyan Liu, Yangqing Deng, Leif Erik Lovblom, Massimo Nardone, Darren A Yuen, Yixiao Chen, Mai Mohsen, Jacob A Udell, Bruce A Perkins, Jasper Stevens, Daan J Touw, Hiddo J L Heerspink, David Z I Cherney, Sunita K S Singh
Förderung
- Heart and Stroke Foundation of Canada
- University Health Network Foundation
- Ajmera Transplant Center
Zitieren
APA
Sridhar, V. S., Kugathasan, L., Lytvyn, Y., Liu, H., Deng, Y., Lovblom, L. E., Nardone, M., Yuen, D. A., Chen, Y., Hua, J., Aronson, Y., Mohsen, M., Kim, S. J., Udell, J. A., Perkins, B. A., Stevens, J., Touw, D. J., Heerspink, H. J. L., Cherney, D. Z. I., & Singh, S. K. S. (2026). Efficacy, Mechanisms, and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology, 21(4), 664-679. https://doi.org/10.2215/cjn.0000000951
Vancouver
Sridhar VS, Kugathasan L, Lytvyn Y, Liu H, Deng Y, Lovblom LE, et al. Efficacy, Mechanisms, and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology. 2026;21(4):664-679. doi:10.2215/cjn.0000000951
BibTeX
@article{Sridhar2026,
author = {Sridhar, Vikas S and Kugathasan, Luxcia and Lytvyn, Yuliya and Liu, Hongyan and Deng, Yangqing and Lovblom, Leif Erik and Nardone, Massimo and Yuen, Darren A and Chen, Yixiao and Hua, Jonathan and Aronson, Yarden and Mohsen, Mai and Kim, S Joseph and Udell, Jacob A and Perkins, Bruce A and Stevens, Jasper and Touw, Daan J and Heerspink, Hiddo J L and Cherney, David Z I and Singh, Sunita K S},
title = {Efficacy, Mechanisms, and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients},
journal = {Clinical Journal of the American Society of Nephrology},
year = {2026},
volume = {21},
number = {4},
pages = {664--679},
doi = {10.2215/cjn.0000000951}
}
EUVIMED